Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real-world evidence for the effectiveness, safety and tolerability of Ribociclib + aromatase inhibitor in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer

Next Previous
Search
Trial Profile

Real-world evidence for the effectiveness, safety and tolerability of Ribociclib + aromatase inhibitor in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ribociclib (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RIBANNA

Most Recent Events

  • 24 Oct 2023 Results of 5th interim analysis ( n=1377, At data cutoff Sep 6, 2022) assessing the efficacy, safety, and tolerability for elderly patients, presented at the 48th European Society for Medical Oncology Congress.
  • 24 Oct 2023 Interim Results presented at the 48th European Society for Medical Oncology Congress
  • 24 Oct 2023 Interim Results (At data cutoff Sep 6, 2022, n=2581) assessing therapy management for RIB, including therapy-related adverse events (AEs), dose adjustment, and efficacy outcomes in special subgroups presented at the 48th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top